Scoop: Med­Im­mune chief Bahi­ja Jal­lal is leav­ing As­traZeneca and join­ing the trek in­to biotech

Six years af­ter As­traZeneca’s then new CEO Pas­cal So­ri­ot named Bahi­ja Jal­lal pres­i­dent of the big Med­Im­mune sub­sidiary in Gaithers­burg, MD, putting her at the cen­ter of the com­pa­ny’s R&D turn­around plans, the long­time phar­ma ex­ec is join­ing the great mi­gra­tion of in­dus­try pro­fes­sion­als to biotech.

Eliot Forster

Jal­lal is tak­ing the helm at Im­muno­core next week, a promi­nent TCR play­er in the UK which has been go­ing through a re­mark­able shake­up af­ter the orig­i­nal team un­der CEO Eliot Forster — now chief at F-star — ei­ther left or were forced out. Im­muno­core was able to raise $320 mil­lion a lit­tle more than 3 years ago — a time when that kind of mon­ey was still able to cause as­ton­ish­ment in the in­dus­try.

This wasn’t the first such biotech job to come along, Jal­lal tells me in an ex­clu­sive in­ter­view ahead of the an­nounce­ment. “But when the right one is there you jump on it.”

The job starts on Mon­day, and Jal­lal says she feels like “a kid in a can­dy store” when it comes to Im­muno­core, a com­pa­ny with a broad plat­form that is built to ac­com­mo­date on­col­o­gy as well as in­fec­tious dis­eases and au­toim­mune con­di­tions.

And Jal­lal isn’t the on­ly se­nior As­traZeneca ex­ec head­ing to new biotech fields. The Wall Street Jour­nal re­ports to­day that Mark Mal­lon — cur­rent EVP in charge of port­fo­lio strat­e­gy — is on his way to take the CEO job at Iron­wood, as that com­pa­ny splits up un­der pres­sure and Pe­ter Hecht leaves to run the R&D spin­out.

An­drew Hotchkiss

Over the past year-plus Im­muno­core has run in­to some se­vere tur­bu­lence af­ter it tried to shop a new round at its old uni­corn val­u­a­tion. Po­ten­tial in­vestors weren’t ready to buy in, trig­ger­ing an ex­o­dus at the top and a move up for chief com­mer­cial of­fi­cer An­drew Hotchkiss as in­ter­im chief.

Jal­lal says Hotchkiss has done a great job this year, which in­cludes ink­ing a ma­jor new pact with Genen­tech, and he’ll go back to con­cen­trat­ing on his com­mer­cial fo­cus with an eye on ad­vanc­ing Im­muno­core’s late-stage can­cer ther­a­py to­ward the mar­ket.

“I can tell you there’s been a lot of progress in the past year,” she adds. “Next week we’re go­ing to JP­Mor­gan and share the sto­ry with the in­vestor com­mu­ni­ty and oth­ers. My in­ten­tion is to bring re­as­sur­ance to in­vestors that I will bring sta­bil­i­ty to the or­ga­ni­za­tion, bring the best team and have the vi­sion we can all work to­geth­er and show them why I am join­ing the com­pa­ny.”

Mene Pan­ga­los

Jal­lal was one of three top R&D ex­ecs So­ri­ot picked for the Big Phar­ma’s turn­around in 2013. Brig­gs Mor­ri­son left sev­er­al years ago to run Syn­dax. That leaves Mene Pan­ga­los and his new col­leagues to run the show at As­traZeneca’s re­search and de­vel­op­ment op­er­a­tions.

There’s no im­me­di­ate word on who will re­place Jal­lal at Med­im­mune, where she steered 5 drugs to an ap­proval, in­clud­ing their check­point play­er Imfinzi.


Im­age: Bahi­ja Jal­lal. MED­IM­MUNE

2023 Spot­light on the Fu­ture of Drug De­vel­op­ment for Small and Mid-Sized Biotechs

In the context of today’s global economic environment, there is an increasing need to work smarter, faster and leaner across all facets of the life sciences industry.  This is particularly true for small and mid-sized biotech companies, many of which are facing declining valuations and competing for increasingly limited funding to propel their science forward.  It is important to recognize that within this framework, many of these smaller companies already find themselves resource-challenged to design and manage clinical studies themselves because they don’t have large teams or in-house experts in navigating the various aspects of the drug development journey. This can be particularly challenging for the most complex and difficult to treat diseases where no previous pathway exists and patients are urgently awaiting breakthroughs.

Up­dat­ed: FDA re­mains silent on or­phan drug ex­clu­siv­i­ty af­ter last year's court loss

Since losing a controversial court case over orphan drug exclusivity last year, the FDA’s Office of Orphan Products Development has remained entirely silent on orphan exclusivity for any product approved since last November, leaving many sponsors in limbo on what to expect.

That silence means that for more than 70 orphan-designated indications for more than 60 products, OOPD has issued no public determination on the seven-year orphan exclusivity in the Orange Book, and no new listings of orphan exclusivity appear in OOPD’s searchable database, as highlighted recently by George O’Brien, a partner in Mayer Brown’s Washington, DC office.

Albert Bourla, Pfizer CEO (Efren Landaos/Sipa USA/Sipa via AP Images)

Pfiz­er makes an­oth­er bil­lion-dol­lar in­vest­ment in Eu­rope and ex­pands again in Michi­gan

Pfizer is continuing its run of manufacturing site expansions with two new large investments in the US and Europe.

The New York-based pharma giant’s site in Kalamazoo, MI, has seen a lot of attention over the past year. As a major piece of the manufacturing network for Covid-19 vaccines and antivirals, Pfizer is gearing up to place more money into the site. Pfizer announced it will place $750 million into the facility, mainly to establish “modular aseptic processing” (MAP) production and create around 300 jobs at the site.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Vas Narasimhan, Novartis CEO (Thibault Camus/AP Images, Pool)

No­var­tis bol­sters Plu­vic­to's case in prostate can­cer with PhI­II re­sults

The prognosis is poor for metastatic castration-resistant prostate cancer (mCRPC) patients. Novartis wants to change that by making its recently approved Pluvicto available to patients earlier in their course of treatment.

The Swiss pharma giant unveiled Phase III results Monday suggesting that Pluvicto was able to halt disease progression in certain prostate cancer patients when administered after androgen-receptor pathway inhibitor (ARPI) therapy, but without prior taxane-based chemotherapy. The drug is currently approved for patients after they’ve received both ARPI and chemo.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Rick Modi, Affinia Therapeutics CEO

Ver­tex-part­nered gene ther­a­py biotech Affinia scraps IPO plans

Affinia Therapeutics has ditched its plans to go public in a relatively closed-door market that has not favored Nasdaq debuts for the drug development industry most of this year. A pandemic surge in 2020 and 2021 opened the doors for many preclinical startups, which caught Affinia’s attention and gave the gene therapy biotech confidence in the beginning days of 2022 to send in its S-1.

But on Friday, Affinia threw in the S-1 towel and concluded now is not the time to step onto Wall Street. The biotech has put out few public announcements since the spring of this year. Endpoints News picked the startup as one of its 11 biotechs to watch last year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Af­ter M&A fell through, Ther­a­peu­tic­sMD sells hor­mone ther­a­py, con­tra­cep­tive ring for $140M cash plus roy­al­ties

TherapeuticsMD, a women’s health company whose one-time billion-dollar valuation seems a distant memory as its blockbuster aspirations petered out, is finally cashing out.

Australia’s Mayne Pharma is paying $140 million upfront to license essentially TherapeuticsMD’s whole portfolio, including two prescription drugs that treat conditions relating to menopause, a contraceptive vaginal ring as well as its prescription prenatal vitamin brands.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Big week for Alzheimer’s da­ta; As­traZeneca buys cell ther­a­py start­up; Dig­i­tal ther­a­peu­tics hits a pay­er wall; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

You may start to notice more stories exclusively available to Premium subscribers. This week alone, paid subscribers can read our in-depth reporting on Alzheimer’s data, digital therapeutics and Allogene’s cell therapy for solid tumors, as well as scoops on Twitter ads and Catalent. With your support, we can keep growing our team and spend more time on quality work. We have both individual and company plans available — check them out to unlock the full Endpoints experience.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Yuling Li, Innoforce CEO

In­no­force opens new man­u­fac­tur­ing site in Chi­na

Innoforce is off to the races at its new site in the city of Hangzhou, China.

The Chinese CDMO announced last week that it has started manufacturing at the new facility, which was built to offer process development and manufacturing operations for RNA, plasmid DNA, viral vectors and other cell therapeutics. It will also serve as Innoforce’s corporate HQ.

The company said it’s investing more than $200 million in the 550,000-square-foot manufacturing base for advanced therapies. The GMP manufacturing facility features space for producing plasmids with three 30-liter bioreactors. For viral vector manufacturing, Innoforce also has 200- and 500-liter bioreactors at its disposal, along with eight suites to make cell therapies. The site also includes several labs and warehouse spaces.

FDA grants or­phan drug des­ig­na­tion to Al­ger­non's ifen­prodil, while ex­clu­siv­i­ty re­mains un­clear

As the FDA remains silent on orphan drug exclusivity in the wake of a controversial court case, the agency continues to hand out new designations. The latest: Algernon Pharmaceuticals’ experimental lung disease drug ifenprodil.

The Vancouver-based company announced on Monday that ifenprodil received orphan designation in idiopathic pulmonary fibrosis (IPF), a chronic lung condition that results in scarring of the lungs.  Most IPF patients suffer with a dry cough, and breathing can become difficult.